

# The GSK Respiratory Portfolio

## The ELLIPTA family of products

### COPD

#### LAMA

**INCRUSE** ELLIPTA  
umeclidinium



62.5 mcg

#### LAMA/LABA

**ANORO** ELLIPTA  
umeclidinium/vilanterol



62.5/25 mcg

#### ICS/LABA

**BREO** ELLIPTA  
fluticasone furoate/vilanterol  
100/25 mcg for COPD



100/25 mcg

#### ICS/LAMA/LABA

**TRELEGY** ELLIPTA  
fluticasone furoate/umeclidinium/vilanterol



100/62.5/25 mcg

INCRUSE ELLIPTA (umeclidinium) is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. INCRUSE ELLIPTA is not indicated for the relief of acute deterioration of COPD.

Please consult the Product Monograph for INCRUSE ELLIPTA at [gsk.ca/incruse/en](http://gsk.ca/incruse/en) for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

ANORO ELLIPTA (umeclidinium/vilanterol) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta<sub>2</sub>-agonist (LABA) indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ANORO ELLIPTA is not indicated for the relief of acute deterioration of COPD. ANORO ELLIPTA is not indicated for the treatment of asthma. The safety and efficacy of ANORO ELLIPTA in asthma have not been established.

Please consult the Product Monograph for ANORO ELLIPTA at [gsk.ca/anoro/en](http://gsk.ca/anoro/en) for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

#### COPD

BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg is a combination of an inhaled corticosteroid (ICS) and a long-acting beta<sub>2</sub>-adrenergic agonist (LABA), indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations.

BREO ELLIPTA 100/25 mcg once daily is the only strength indicated for the treatment of COPD. BREO ELLIPTA 200/25 mcg is not indicated for patients with COPD. There is no additional benefit of the 200/25 mcg dose compared to the 100/25 mcg dose and there is a potential increased risk of pneumonia and systemic corticosteroid-related adverse reactions. BREO ELLIPTA is not indicated for the relief of acute bronchospasm.

Please consult the Product Monograph for BREO ELLIPTA at [gsk.ca/breo/en](http://gsk.ca/breo/en) for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) 100/62.5/25 mcg is a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta<sub>2</sub>-adrenergic agonist (LABA), indicated in patients who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA:

- For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- To reduce exacerbations of COPD in patients with a history of exacerbations.

TRELEGY ELLIPTA is not indicated for the relief of acute bronchospasm and is not indicated for the treatment of asthma.

Please consult the Product Monograph for TRELEGY ELLIPTA at [gsk.ca/trelegy/pm](http://gsk.ca/trelegy/pm) for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

### ASTHMA

#### ICS/LABA

**BREO** ELLIPTA  
fluticasone furoate/vilanterol



100/25 mcg & 200/25 mcg

#### ICS

**ARNUITY** ELLIPTA  
fluticasone furoate



100 mcg & 200 mcg

#### Asthma

BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease.

BREO ELLIPTA, an ICS/LABA combination, should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as an ICS, or whose disease severity clearly warrants treatment with both an ICS and a LABA.

BREO ELLIPTA is not indicated for patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta<sub>2</sub>-agonist or for patients whose asthma can be successfully managed by ICS along with occasional use of a rapid onset, short duration, inhaled beta<sub>2</sub>-agonist. BREO ELLIPTA is not indicated for the relief of acute bronchospasm. BREO ELLIPTA 200/25 mcg is not indicated for COPD.

Please consult the Product Monograph for BREO ELLIPTA at [gsk.ca/breo/en](http://gsk.ca/breo/en) for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

ARNUITY ELLIPTA (fluticasone furoate) is indicated for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older. ARNUITY ELLIPTA is not indicated for the relief of acute bronchospasm.

Please consult the Product Monograph for ARNUITY ELLIPTA at [gsk.ca/arnuity/en](http://gsk.ca/arnuity/en) for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-387-7374. To report an adverse event, please call 1-800-387-7374.

COPD = Chronic obstructive pulmonary disease  
LAMA = Long-acting muscarinic antagonist  
LABA = Long-acting beta<sub>2</sub>-agonist  
ICS = Inhaled corticosteroid

Trademarks are owned by or licensed to the GSK group of companies.  
ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA were developed in collaboration with INNOVIVA  
© 2019 GSK group of companies or its licensor.

Simply remove film from backer.  
No tape or adhesive required.  
Clings to most surfaces.  
Removable and repositionable.